We are live on ! Find out more
CC

Cannell & Co Portfolio holdings

AUM $3.15B
1-Year Est. Return 30.62%
This Fund
S&P 500
This Quarter Est. Return
-3.98%
1 Year Est. Return
+30.62%
3 Year Est. Return
+51.59%
5 Year Est. Return
+187.25%
10 Year Est. Return
+311.51%
AUM
$2.61B
AUM Growth
-$176M
Cap. Flow
-$7.57M
Cap. Flow %
-0.29%
Top 10 Hldgs %
29.38%
Holding
278
New
8
Increased
76
Reduced
97
Closed
17

Top Buys

Rank Stock Value
1
EQT icon
EQT Corp
EQT
+$43.2M
2
TECK icon
Teck Resources
TECK
+$40.4M
3
SMCI icon
Super Micro Computer
SMCI
+$24.4M
4
BN icon
Brookfield
BN
+$19.2M
5
HCA icon
HCA Healthcare
HCA
+$17M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$47M
2
CCK icon
Crown Holdings
CCK
+$38.1M
3
AEM icon
Agnico Eagle Mines
AEM
+$32M
4
SLG icon
SL Green Realty
SLG
+$21.7M
5
KMX icon
CarMax
KMX
+$19.1M

Sector Composition

Rank Sector Weight
1 Technology 18.87%
2 Financials 15.85%
3 Healthcare 13.12%
4 Consumer Discretionary 10.92%
5 Materials 9.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VALE icon
276
Vale
VALE
$62.6B
-63,000
Closed -$922K
CNSL
277
DELISTED
Consolidated Communications Holdings, Inc.
CNSL
-10,000
Closed -$70K
APRN
278
DELISTED
Blue Apron Holdings, Inc. Class A Common Stock
APRN
-1,672
Closed -$73K

Similar funds

Cannell & Co's Q3 2022 Portfolio in Review

As of Q3 2022, Cannell & Co held 278 positions worth $2.61B, down 6.3% from $2.78B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Cannell & Co's Q3 2022 filing shows 8 new, 76 increased, 97 reduced and 17 closed positions. Its largest new stake was EQT Corp: 996,050 shares worth $40.6M. The largest sale was AstraZeneca, an estimated $47M.

By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Financials and Healthcare.

  • Cannell & Co's largest Q3 2022 buy was EQT Corp: 996,050 shares worth $40.6M.
  • Cannell & Co added most to Teck Resources in Q3 2022, an estimated $40.4M increase.
  • Cannell & Co's biggest Q3 2022 reduction was Crown Holdings, cutting an estimated $38.1M.
  • Cannell & Co fully exited AstraZeneca in Q3 2022, selling an estimated $47M.
  • Cannell & Co's ten largest holdings make up 29% of its $2.61B portfolio in Q3 2022.
  • Cannell & Co opened 8 new positions and closed 17 in Q3 2022.
  • Cannell & Co's portfolio value fell 6.3% quarter-over-quarter to $2.61B.

Based on Cannell & Co's 13F filing for Q3 2022, filed 2 Nov 2022.